TAPERANK
Open the app
MOVER · THU OCT 22 2026

Why ESLA rose 32.5% on Oct 22 2026: clinical trial update

ESLA+32.5%on Thu Oct 22 2026

Estrella Immunopharma, Inc. Common Stock was up 32.5% on the day at $0.7287, ranked #2 on 311× its usual five-minute volume, when TapeRank recorded this spike at 10:39 ET during regular hours.

THE DAY ON THE LIST · 1 EVENT

  1. 10:39 ET
    MOVER · REGULAR

    $0.7287 · ▲ 32.5% ON THE DAY · 311× 5M RVOL · RANK #2

    STRETCHEDCONFIDENCE4/5

    ESLA is up 21.6% on the day and accelerating, following an early clinical update on a single patient in the dose-expansion phase. Although the prior high-dose cohort showed a 100% Month 1 complete response rate among evaluable patients, the new evidence remains very small and preliminary relative to the sharp move.

    WHYUp 21.6% with an additional 8.1% in five minutes is large versus a single-patient safety update, even with supportive nine-patient early-phase data.
    ANALYZED 10:31 ET · 8 MIN AGO · OPENAI/GPT-5.6-LUNA
    THE ROW AND SESSION LEVELS AT 10:39 ET
    LAST0.7287
    DAY▲ 32.5%
    5 MIN▲ 7.17%
    5M RVOL311×
    5M $VOL$549K
    FLOAT*43.5M
    RANK#2
    SESSIONREGULAR
    VWAP0.6566
    HOD0.7086
    LOD0.5400
    OR HIGH0.6209
    OR LOW0.5550
    PREV CLOSE0.5500
    PM HIGH0.6191
    PM LOW0.5400
    GAP▲ 2.09%

    * FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE

THE SESSION

  • 09:30 ETOpened at $0.5615, +2.1% on the previous close of $0.5500
  • 09:33 ETRegular-session low, $0.5550
  • 14:47 ETRegular-session high, $0.7588
  • 15:59 ETLast trade of the regular session, $0.7300, +32.7% on the previous close of $0.5500
  • Volume: 6.2M shares in regular hours, 109K before the open

ESLA opened at $0.5615, briefly dipped to a $0.5550 low, then advanced through the session to reach $0.7588 at 14:47 ET before ending regular trading at $0.7300, up 32.7% from the previous close. TapeRank’s read tied the move to an early clinical trial update on a single patient in the dose-expansion phase, while noting that the evidence was small and preliminary despite supportive nine-patient early-phase data; Benzinga also reported on the surge. No halts occurred.

WRITTEN THU OCT 22 2026 16:00 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE

FILINGS AND NEWS · 24H BEFORE THE MOVE

On the tape right now

WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY

01
ECGSURGING 0:05
79.71
▼ 29.3%
▼ 1.41%
41.0×
FAD
$6.2M
51.1M*
STRETCHED
02
CAVASURGING 0:00
64.78
▲ 7.4%
▲ 1.30%
9.3×
ORBHODVWH
$11.6M
116.8M*
UNEXPLAINED
03
URGNSURGING 0:00
29.16
▼ 15.2%
▼ 1.29%
15.6×
FAD
$1.4M
48.9M*
JUSTIFIED
04
MPTISURGING 0:00
64.15
▼ 1.5%
▲ 0.96%
23.8×
VWH
$637K
4.3M*
UNEXPLAINED
05
LSPDSURGING 0:00
11.52
▲ 4.9%
▼ 1.24%
16.5×
ORB
$426K
133.3M*
UNEXPLAINED
06
CRCTSURGING 0:00
8.90
▲ 49.2%
▼ 0.72%
15.1×
GAPORBVWHEXT
$395K
54.7M*
STRETCHED
07
BROSSURGING 0:00
43.97
▲ 0.9%
▼ 0.91%
4.0×
FAD
$4.3M
137.9M*
UNEXPLAINED
08
LMRICOOLING 1:35
12.85
▲ 14.5%
▲ 1.06%
132×
ORBHODVWH
$1.7M
—
UNEXPLAINED
Open the full list